EQ EQ
Company Profile ↓Company Overview
EQ (EQ) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 61.5% CAGR over the past five years.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue +13.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 61.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 61.48% |
| 1 Year: | 13.89% |
Stock Price Performance
| 1 Year: | +291.07% |
| 6 Months: | +45.03% |
| 3 Months: | +5.80% |
| 1 Month: | -23.96% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)36.45 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 61.5% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 31.6% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.88M | 9.12M | 8.87M | 10.69M | 13.85M | 12.16M | - | - | - | - |
| Operating Income | - | -83.71K | - | -1.04M | -1.12M | -2.23M | - | -6.35M | -6.44M | -6.32M | - | -7.45M | -6.61M | -6.52M | - | -8.70M | -8.84M | -9.86M | -37.33M | -13.55M | -13.24M | -4.11M | -3.59M | -3.62M | -2.79M | -100.00K | -679.00K | -8.87M | -6.23M | -4.58M | -5.61M |
| Net Income | -947.30K | -141.03K | -1.11M | -1.58M | -1.76M | -4.92M | -4.99M | -5.95M | -6.07M | -6.01M | -7.57M | -7.84M | -6.46M | -6.60M | -8.92M | -8.99M | -9.16M | -10.28M | -37.42M | -14.13M | -13.65M | -3.94M | -3.34M | -3.71M | -2.73M | 468.00K | -7.00K | -8.65M | -5.74M | -4.23M | -5.31M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.31 | -0.35 | -1.17 | -0.41 | -0.40 | -0.11 | -0.10 | -0.11 | -0.08 | 0.01 | 0.00 | -0.24 | -0.16 | -0.06 | -0.06 |
| R&D Expense | - | 49.95K | - | 663.00K | 540.00K | 1.22M | - | 3.76M | 4.25M | 4.18M | - | 4.71M | 3.89M | 4.22M | - | 5.88M | 5.99M | 6.96M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 15.76M | 36.08M | 41.09M | - |
| Operating Income | -8.62M | -26.73M | -29.55M | -37.79M | -62.08M | -14.52M | -8.27M | -23.63M |
| Net Income | -13.25M | -25.60M | -29.81M | -39.05M | -62.43M | -13.34M | -8.07M | -22.40M |
| Diluted EPS | - | - | - | -1.36 | -1.85 | -0.38 | -0.23 | -0.39 |
| R&D Expense | 4.94M | 17.64M | 19.38M | 26.38M | 37.55M | 37.04M | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 7.15M | 67.16M | 55.54M | 85.43M | 85.41M | 78.42M | 50.53M | 25.60M | 31.89M |
| Total Equity | 0 | -2.25M | 64.94M | 41.85M | 69.85M | 66.50M | 31.94M | 22.57M | 19.06M | 28.60M |
| Cash & Equivalents | - | 7.10M | 28.51M | 13.22M | 23.98M | 50.37M | 59.11M | 23.22M | 18.09M | 30.28M |
| Long Term Debt | - | - | - | 9.68M | 8.28M | 8.75M | 3.24M | - | - | - |
| Total Liabilities | - | 9.40M | 2.23M | 13.69M | 15.57M | 18.90M | 46.48M | 27.96M | 6.54M | 3.29M |
| Current Liabilities | - | 568.82K | 2.03M | 3.88M | 7.25M | 8.91M | 32.04M | 27.57M | 6.36M | 2.93M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.53M | -22.95M | -24.62M | -32.08M | -8.73M | -21.78M | -19.03M | -22.75M |
| Investing Cash Flow | -37.43M | -2.17M | -18.59M | 27.41M | 18.68M | -4.76M | 13.81M | 4.46M |
| Financing Cash Flow | 66.36M | 9.84M | 53.95M | 31.06M | -1.22M | -9.23M | 164.00K | 30.43M |
| Capital Expenditure | -35.00K | -74.00K | -202.00K | -57.00K | -279.00K | -50.00K | -85.00K | -48.00K |
| Free Cash Flow | -7.56M | -23.02M | -24.83M | -32.14M | -9.01M | -21.83M | -19.11M | -22.79M |
| Share Buybacks | - | - | - | - | - | 260.00K | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -393.9% | -40.2% | -20.1% | - |
| Net Margin % | - | - | - | - | -396.1% | -37.0% | -19.6% | - |
| ROE % | -20.4% | -61.2% | -42.7% | -58.7% | -195.4% | -59.1% | -42.3% | -78.3% |
| ROCE % | -13.2% | -51.7% | -37.8% | -49.4% | -133.8% | -63.3% | -43.0% | -81.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EQ
Analysts Grow More Confident In Equillium’s (EQ) Lead Asset EQ504
Equillium, Inc. (NASDAQ:EQ), with a year-to-date gain of 89.68% and upside potential of 121.10%, secures a spot on our list of hot biotech stocks under $5 to buy. Two analyst updates landed on the same day, both pointing to growing convicti…
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on June 1, 2026, the Compensa…
Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1
Equillium (NASDAQ:EQ) Chief Scientific Officer Stephen Connelly outlined new preclinical data during a company webinar focused on the relationship between the aryl hydrocarbon receptor, or AhR, and miR-124, a microRNA implicated in inflamma…
Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis
Virtual webinar to be held on Wednesday, May 27 at 11:00 AM ETLA JOLLA, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory …
Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights
Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafter Equillium appoints Snehal Naik, Ph.D., as Chief Development Officer to lead clinical development and medical …
Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event
LA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be presentin…
EQ — Frequently Asked Questions
What is the current share price of EQ?
As of 2026-08-05 17:25 PDT, EQ trades at $2.19 on NASDAQ/NYSE. Its 52-week range is $0.50 to $3.20.
What is the P/E ratio of EQ?
EQ trades at a trailing price-to-earnings (P/E) ratio of -5.62.
What is the return on equity (ROE) of EQ?
EQ has a return on equity (ROE) of -78.32%. Its return on capital employed (ROCE) is -81.63%.
Is EQ a good stock to buy?
This page provides a data-driven analysis of EQ, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.